Ishare Nq Biotch ETF (IBB) 255.48 $IBB Jim Cramer --

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ishare Nq Biotch ETF (IBB) 255.48 $IBB

Jim Cramer -- Biotech Stocks' Window of Opportunity
at The Street - Fri Mar 25, 1:30PM CDT
Jim Cramer says that biotech stocks could have a window of opportunity to rally as Valeant rebounds and as politicians lay off the sector.
VRX: 31.09 (-2.34), IBB: 255.48 (+1.22)

Trader's Notebook: Biotech Has Momentum
at The Street - Wed Mar 23, 8:00AM CDT
Also, oil data surprise and E-mini bullishness wanes.
XBI: 50.05 (+0.18), IBB: 255.48 (+1.22)

Jim Cramer -- Bernie Sanders Dropout Could Rally Biotech Stocks
at The Street - Tue Mar 22, 11:57AM CDT
If Hillary Clinton can knock Bernie Sanders from the Democratic presidential race, it could spur a rally in the biotech sector, says Jim Cramer.
VRX: 31.09 (-2.34), AMGN: 149.24 (+0.48), IBB: 255.48 (+1.22)

Trader's Notebook: Reduced Volume Alert
at The Street - Tue Mar 22, 8:00AM CDT
Avoid over-trading at all costs.
IBB: 255.48 (+1.22)

After Yesterday's Rally of 1.95% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 21, 12:14PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $250.26 to a high of $257.66. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $255.50 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 255.48 (+1.22)

Better Buy: Intuitive Surgical, Inc. vs. Medtronic PLC
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 21, 8:01AM CDT
  The medical-device industry is expected to grow right along with average life spans and incomes among developed nations. Trying to ride this trend by investing in most drugmakers has been disastrous recently. The  Nasdaq Biotechnology Index ,...
ISRG: 583.31 (-3.02), MDT: 73.97 (-0.53), XPH: 39.39 (-0.19), IBB: 255.48 (+1.22), IHI: 119.22 (-0.51)

3 Biotech Stocks to Buy in March
Cheryl Swanson, Kristine Harjes, and Brian Feroldi, The Motley Fool - Motley Fool - Fri Mar 18, 3:39PM CDT
Looking for stocks to buy? It's time to get in some shots before the weather warms up. Flickr: Creative Commons March--as the saying goes--comes in like a lion and goes out like a lamb. And biotechs may be about to do the same, although it's...
PTLA: 20.27 (-8.35), IBB: 255.48 (+1.22), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)

3 Biotech Stocks to Buy on Sale
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Mar 18, 7:22AM CDT
Image Source TBIT via pixabay The broad S&P 500 has rallied over the last few weeks, and it has largely recovered from the beating that it took early in the year. The biotech sector, however, hasn't fared quite as well. Many biotech stocks...
AGN: 279.32 (-1.99), GERN: 2.86 (+0.08), PFE: 30.08 (-0.11), IBB: 255.48 (+1.22), CHRS: 19.41 (+0.30)

Rev's Forum: Be Careful About Being Too Negative Ahead of the Fed
at The Street - Wed Mar 16, 6:49AM CDT
The market still loves to love the Fed.
VRX: 31.09 (-2.34), IBB: 255.48 (+1.22)

The Trader Daily: Valeant's Crash Scatters Debris
at The Street - Wed Mar 16, 6:00AM CDT
Bad news was widespread amid biotech and related sectors.
PPH: 57.22 (-0.23), VRX: 31.09 (-2.34), XBI: 50.05 (+0.18), IBB: 255.48 (+1.22)

Why Exelixis' Stock Dropped 10% on Tuesday
George Budwell, The Motley Fool - Motley Fool - Wed Mar 09, 9:30AM CST
What: Shares of Exelixis , a small-cap biopharma focusing on the development of cancer treatments, fell by 10.42% yesterday on higher-than-normal volume. The good news is that this double-digit decline doesn't appear to be linked to a...
IBB: 255.48 (+1.22), EXEL: 4.04 (+0.07)

Why It Makes Sense To 'Bet The Farm' With A Portion Of Your Portfolio
William Koldus, CFA, CAIA - at Seeking Alpha - Wed Mar 09, 9:28AM CST

KMI: 18.09 (+0.34), USO: 10.06 (-0.05), CNX: 10.94 (+0.50), UNG: 6.40 (+0.10), FCX: 10.11 (+0.36), IBB: 255.48 (+1.22), CLD: 2.02 (+0.02), UNT: 9.32 (+0.05), BTU: 2.56 (+0.16), SPY: 203.12 (-0.09), TCK: 7.36 (+0.07), CHK: 4.25 (+0.12), SUNE: 1.21 (-0.06), X: 15.78 (+0.94), SWN: 7.38 (+0.03)

3 Reasons Jazz Pharmaceuticals Stock Could Rise in 2016
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 08, 12:20PM CST
Over the past 12 months, Jazz Pharmaceuticals stock has fallen along with the  Nasdaq Biotechnology ETF . Public outcry over rising prescription drug prices is largely to blame for the losses seen in the biotechnology index (and across the...
JAZZ: 118.59 (-2.52), IBB: 255.48 (+1.22)

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.52% Rise
Comtex SmarTrend(R) - Mon Mar 07, 5:11PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $260.92 to a high of $272.07. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $269.79 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 255.48 (+1.22)

Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 2.52% Yesterday
Comtex SmarTrend(R) - Mon Mar 07, 5:11PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $260.92 to a high of $272.07. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $269.79 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 255.48 (+1.22)

So Many Topics, So Few Columns
at The Street - Sat Mar 05, 11:00AM CST
In response to reader input, here's what to look for from me.
XBI: 50.05 (+0.18), IBB: 255.48 (+1.22), BAC: 13.68 (+0.06), GDX: 19.46 (+0.43)

5 Revenant Sectors Echo Leo's Oscar-Winning Performance
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 2:30PM CST
Like the determined Hugh Glass, these sectors stood up to escape a bear market following massive sell-offs at the start of the year and register solid gains over the past month.
AMZN: 582.95 (+13.32), UNH: 128.59 (-1.20), XLY: 77.55 (+0.10), DIS: 97.22 (+0.39), IBB: 255.48 (+1.22), XOM: 83.98 (+0.23), XLV: 67.39 (-0.03), JPM: 59.48 (-0.46), MRK: 53.07 (-0.01), DD: 63.95 (+0.20), XLFS: 28.29 (-0.56), BRK.B: 140.11 (-0.85), CVX: 94.85 (+1.26), DOW: 51.32 (+0.14)

Trader's Notebook: Is It Biotech's Turn to Outperform?
at The Street - Fri Mar 04, 8:00AM CST
The biotechnology sector has lagged horribly.
VALE: 4.04 (+0.20), XBI: 50.05 (+0.18), IBB: 255.48 (+1.22), TWI: 5.42 (+0.35)

Small Caps And Biotech Remain Weak Links Despite The Recent Rebound
Michael Harris - Seeking Alpha - Thu Mar 03, 1:40PM CST
In an article on June 20, 2015, I concluded that the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) and iShares Russell 2000 ETF (NYSEARCA: IWM ) were bubble markets, after analyzing their top 20 holding. Due to the correction that followed, IBB...
IBB: 255.48 (+1.22), IWM: 107.20 (+0.32)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shanghai Masters: Minhang's Vibe Enchants Visitors

Updated Category News Views 74

Minhang's Unique Blend of Action and Relaxation Tennis fans and journalists aren't exactly flocking to Minhang for a typical sports event feel. During the 2026 Rolex Shanghai Masters, something magical happened—intense tennis matches inside the court and a serene culinary oasis outside. You'd think these two worlds wouldn't mix, but Minhang pulled it off spectacularly....

Continue Reading
Understanding Cataracts: What Investors Should Know

Updated Category News Views 156

The Subtle Slowdown in Vision When it comes to cataracts, things don't just suddenly hit you like a ton of bricks. It’s a slow burn—cataracts develop over months or even years. Your vision starts feeling like it’s giving up on high definition. The lens in your eye starts to get cloudy, like a fog rolling in on a morning drive. You're not going to wake up one day...

Continue Reading
GrayMar’s Strategic Southeast Boost Could Reshape Market

Updated Category News Views 61

GrayMar’s Big Southeast Step Alright, let’s face it—when a company like GrayMar Environmental Services decides to go on a shopping spree, it’s a signal worth heeding, especially if they’ve got their eyes on expanding their empire across the Southeast. This time, it’s not just another map pin but a strategic play with heft. GrayMar’s picked up six locations...

Continue Reading
Replit Wins 2026 Microsoft Startup Partner Award

Updated Category News Views 76

Replit's Triumph in the Microsoft Ecosystem If there's one thing you come to expect from this dizzying dance of technology and business, it's that standout players get their due when they push the envelope. Replit just snagged a gleaming accolade by being named Microsoft's 2026 Partner of the Year for Startups. That's a hefty badge, especially coming from a giant like...

Continue Reading
Xinjiang Farmer Cultivates Community Success and Skills

Updated Category News Views 72

Growing Opportunities Beyond Tradition Zhang Xiying in Urumqi county, Xinjiang Uygur Autonomous Region, is rewriting the farming script with unflagging effort. She's not just tending to her own crops; she's nurturing a whole ecosystem of farmers who're hungry to branch out beyond traditional harvests. Picture this—a farmer turned agricultural technician, helping 19...

Continue Reading
Deadlines Loom for AppLovin Investors in Lawsuit

Updated Category News Views 85

Tough Times Ahead for AppLovin Investors If you're holding any AppLovin shares (NASDAQ: APP) and you caught wind of this class action, it's high time for some reflection. The clock is ticking down to November 16, 2026—just days away—and if you've felt the sting in your pocket over their securities, time's running short to throw your hat in the ring as a lead...

Continue Reading
Insulin Delivery Devices: A Billion-Dollar Surge

Updated Category News Views 45

When's the last time you saw a medical device market promising a $10 billion leap in under five years? Yeah, the insulin delivery devices market's got that kind of upside, projected to skyrocket from $16.92 billion in 2026 to a whopping $26.37 billion by 2031. That's a 9.3% annual growth rate. The numbers and the stakes are both staggering. Regional and Segment Leaders...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 80

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Festo's CIP Safety Module: Impacting Pneumatic Systems

Updated Category News Views 60

Festo's Pneumatic Safety Game-Changer Festo is stirring up quite a fuss at the Automation Fair in Boston this year, and it's not just hot air. Their new CPX-AP-A CIP Safety module is a standout. This jolt of innovation is geared to revolutionize the way safety is approached in pneumatic systems. The key? Seamless integration and robust performance, not to mention a...

Continue Reading
Voyageurs Park Honors Dark Skies with 2026 Recognition

Updated Category News Views 49

Voyageurs' Skyward Triumph: A Stellar Win for Conservation Ah, the night sky. That vast, galaxy-speckled canvas we too often ignore, drowned out by urban light pollution. But hey, not in Voyageurs National Park, no sir. This gem's just snagged the 2026 International Dark Sky Place of the Year Award, handed out by those watchful folks at DarkSky International. It's a...

Continue Reading

Top 5 Most Recently Viewed Articles

Instacart and Ulta Beauty Forge Partnership for Fast Delivery

Updated Category News Views 132

Instacart and Ulta Beauty Join Forces for Same-Day Delivery In an exciting development for beauty enthusiasts and convenience seekers, Instacart (NASDAQ: CART), known for revolutionizing grocery technology in North America, is collaborating with Ulta Beauty (NASDAQ: ULTA), the leading specialty beauty retailer in the United States. This partnership is set to roll out...

Continue Reading
Advanced Wound Care Market Projected to Surge by 2030

Updated Category News Views 149

Observations on the Advanced Wound Care Market Growth The advanced wound care market is on a steady rise, projected to reach a remarkable valuation of $19.32 billion by the end of this decade. This growth trajectory represents a significant compound annual growth rate (CAGR) of 7.6%. Primary drivers for this expansion include the increasing geriatric population and the...

Continue Reading
Octopus AIM VCT 2 plc Enhances Shareholder Value with Buyback

Updated Category News Views 156

Octopus AIM VCT 2 plc Boosting Shareholder Confidence Octopus AIM VCT 2 plc is making significant strides in enhancing shareholder value through its recent share buyback program. The company has successfully purchased a total of 1,089,507 ordinary shares for cancellation. This strategic move reflects Octopus AIM's commitment to reinforcing its market position and...

Continue Reading
Explore ExchangeRight's Resilient $107 Million Investment Strategy

Updated Category News Views 76

ExchangeRight's Impressive $107 Million Portfolio Funding ExchangeRight has recently made headlines in the investment world by fully subscribing its remarkable $107 million Net-Leased Portfolio 66 DST. This achievement highlights the trust and confidence investors have in ExchangeRight, a well-known provider of various real estate DST and REIT investments. This portfolio...

Continue Reading
General Motors Reports Strong Q2 Results, Analysts Adjust Ratings

Updated Category News Views 205

General Motors Surprises with Strong Earnings General Motors Company (NYSE: GM) has recently announced its second quarter results, showcasing better-than-expected performance in both earnings and sales. With adjusted earnings per share reported at $2.53, GM has surpassed analyst forecasts, which estimated the figure to be around $2.40. Concurrently, the company's...

Continue Reading